As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively (By similarity).
Plitzko, Havemeyer, Kunze, Clement: "The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine." in: The Journal of biological chemistry, Vol. 290, Issue 16, pp. 10126-35, (2015) (PubMed).
Jakobs, Mikula, Havemeyer, Strzalkowska, Borowa-Chmielak, Dzwonek, Gajewska, Hennig, Ostrowski, Clement: "The N-reductive system composed of mitochondrial amidoxime reducing component (mARC), cytochrome b5 (CYB5B) and cytochrome b5 reductase (CYB5R) is regulated by fasting and high fat diet in mice." in: PloS one, Vol. 9, Issue 8, pp. e105371, (2014) (PubMed).
Plitzko, Ott, Reichmann, Henderson, Wolf, Mendel, Bittner, Clement, Havemeyer: "The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells." in: The Journal of biological chemistry, Vol. 288, Issue 28, pp. 20228-37, (2013) (PubMed).